Abstract: Prostate cancer (PCa) is defined by dysregulated lipid signaling and is characterized by upregulation of lipid metabolism-related genes including fatty acid binding protein 5 (FABP5), fatty acid synthase (FASN), and monoacylglycerol lipase (MAGL). FASN and MAGL are enzymes that generate cellular fatty acid pools while FABP5 is an intracellular chaperone that delivers fatty acids to nuclear receptors to enhance PCa metastasis. Since FABP5, FASN, and MAGL have been independently implicated in PCa progression, we hypothesized that FABP5 represents a central mechanism linking cytosolic lipid metabolism to pro-metastatic nuclear receptor signaling. Here, we show that the abilities of FASN and MAGL to promote nuclear receptor activation and PCa metastasis are critically dependent upon co-expression of FABP5 in vitro and in vivo. Our findings position FABP5 as a key driver of lipid-mediated metastasis and suggest that disruption of lipid signaling via FABP5 inhibition may constitute a new avenue to treat metastatic PCa.
Introduction
Prostate cancer (PCa) is notorious for hijacking lipid metabolism to fuel its progression. Aggressive tumors often overexpress enzymes like Fatty Acid Synthase (FASN) and Monoacylglycerol Lipase (MAGL) to create a massive internal pool of fatty acids. However, targeting these enzymes individually has been clinically challenging because cancer cells are metabolically flexible—blocking one pathway often leads the cell to find another way to acquire lipids.
This study, published in Scientific Reports, identifies Fatty Acid Binding Protein 5 (FABP5) as a critical "bottleneck" in this process. FABP5 acts as an intracellular chaperone, a "delivery truck" that transports signaling lipids from the cytoplasm to nuclear receptors like PPARγ, triggering the genetic program for metastasis.
FABP5 as the Metabolic Gatekeeper
The researchers employed a "logic gate" approach using weakly metastatic LNCaP cells (low FABP5) and highly metastatic PC3 cells (high FABP5). They found that overexpressing FASN or MAGL in cells lacking FABP5 did nothing to increase migration. The lipids were being produced, but the pro-metastatic "message" wasn't being delivered to the nucleus.
As shown in Figure C, while FASN alone has a negligible effect on migration, its co-expression with FABP5 leads to a synergistic increase in cellular aggressiveness. This confirms that FABP5 is the essential link required for these metabolic enzymes to promote metastasis.
Experimental Evidence and Key Results
The study utilized genetic manipulation (shRNA knockdown), functional migration/invasion assays, and orthotopic mouse models to validate FABP5's role. A key mechanistic insight was that FABP5 must physically enter the nucleus to work; when researchers used a version of FABP5 fused to a Nuclear Export Signal (NES) to trap it in the cytoplasm, the cancer cells remained relatively sedentary.
Further experiments demonstrated the reverse dependency: the pro-migratory effects of FABP5 are reliant on a steady supply of lipids from enzymes like FASN. As seen in Figure B, knocking down FASN in cells overexpressing FABP5 reduced their invasive capacity by roughly 50%, returning them to baseline levels. In vivo, FABP5 knockdown in mouse models led to a dramatic reduction in metastasis to the lungs and femurs compared to controls.
Conclusion and Therapeutic Implications
By positioning FABP5 as the central coordinator of lipid-mediated signaling, this research suggests a new therapeutic strategy. Because FABP5 handles lipids from multiple sources—internal synthesis, recycling, and even external dietary fats—inhibiting this single chaperone could be more effective than targeting individual metabolic enzymes. While genetic knockdown has proven successful in the lab, the next challenge is developing small-molecule FABP5 inhibitors for clinical use in human patients.
Summary updated